drugset / Trial / NCT04861337

Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients

NCT04861337

Phase 4 Completed 552 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This trial aims to explore whether the intraoperative use of remimazolam can reduce the incidence of postoperative nausea and vomiting (PONV) in high-risk patients. According to the Apfel's simplified score, patients with 3 or more of the following factors are at high risk of postoperative nausea and vomiting (PONV), i.e., women, non-smokers, history of PONV, and postoperative use of opioids.

Timeline

Start
2021-05-19
Primary completion
2022-12-31
Completion
2023-04-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Remimazolam Small molecule 0.25 mg/kg

Indications

No indication recorded.